All In Biotech

Drug Trial Radar · NCT07049107

Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects

A Study on the Pharmacokinetic Effects of HRS-8427 Injection on Bupropion and Midazolam in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Jun 23, 2025

Primary completion

Jul 21, 2025

Study completion Jul 21, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-center, open-label, sequential drug interaction study The primary objectives are: To evaluate the pharmacokinetic effects of HRS-8427 injection on the liver drug enzymes CYP2B6 substrate bupropion and CYP3A4 substrate midazolam in healthy subjects.

Conditions

  • Health Volunteer

Interventions

  • HRS-8427Drug

    HRS-8427

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 15 Days
  2. AUC0-tTime frame: 15 Days
  3. AUC0-∞Time frame: 15 Days
  4. TmaxTime frame: 15 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.